Humoral Immunogenicity to SARS-CoV-2 Vaccination in Liver Transplant Recipients: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Jeong-Ju | - |
dc.contributor.author | Yon, Dong Keon | - |
dc.contributor.author | Lee, Seung Won | - |
dc.contributor.author | Shin, Jae Il | - |
dc.contributor.author | Kim, Beom Kyung | - |
dc.date.accessioned | 2022-11-29T05:41:38Z | - |
dc.date.available | 2022-11-29T05:41:38Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1449-2288 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21788 | - |
dc.description.abstract | Solid organ transplant recipients generally show reduced immunogenicity to various vaccines. We aimed to assess the immunogenicity of the immune response among orthotopic liver transplant (OLT) recipients after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. A systematic search was performed to evaluate immunogenicity or adverse events reported after SARS-CoV-2 vaccination. The pooled analysis of 20 studies showed a humoral immune response rate of 0.70 (95% confidence interval [CI], 0.63-0.77) after SARS-CoV-2 vaccination among OLT recipients. The immunogenicity among OLT recipients was significantly lower compared to the overall population and healthy controls, with odds ratios (ORs) of 0.80 and 0.69. However, it was significantly higher than that of patients receiving other organ transplants, especially kidneys, with an OR of 1.50. Male sex, old age, chronic kidney disease, obesity, and multiple or high immunosuppressant doses significantly increased the risk of unresponsiveness in patients with OLT. The overall incidence of any adverse event after vaccination was 0.68 (95% CI, 0.55-0.81), similar to that of control. OLT recipients had an overall humoral immune response rate of 70% after SARS-CoV-2 vaccination, which is lower than that of healthy controls but favourable compared to those of other solid organ transplant recipients. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Ivyspring International Publisher | - |
dc.title | Humoral Immunogenicity to SARS-CoV-2 Vaccination in Liver Transplant Recipients: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.publisher.location | 호주 | - |
dc.identifier.doi | 10.7150/ijbs.77030 | - |
dc.identifier.scopusid | 2-s2.0-85138730234 | - |
dc.identifier.wosid | 000862682900005 | - |
dc.identifier.bibliographicCitation | International Journal of Biological Sciences, v.18, no.15, pp 5849 - 5857 | - |
dc.citation.title | International Journal of Biological Sciences | - |
dc.citation.volume | 18 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 5849 | - |
dc.citation.endPage | 5857 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Life Sciences & Biomedicine - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biology | - |
dc.subject.keywordPlus | RESPONSES | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | COVID-19 | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | liver transplant | - |
dc.subject.keywordAuthor | vaccine | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | immunogenicity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.